Beta Blockers for Dogs in Canada — Top 7 Prescription Options for 2026

Atenolol 25mg holds a best-in-class position for small-breed dogs because its lower tablet strength enables precise, titratable dosing for chronic management of hypertension and some cardiomyopathies. As a beta-1 selective agent it tends to have less bronchial and central nervous system penetration than non-selective propranolol products, and it is often more cost-effective per milligram for long-term therapy compared with higher-strength tablets that require splitting. Compared with sotalol, it lacks Class III antiarrhythmic effects but offers a simpler safety profile that can reduce monitoring costs in suitable patients.

Atenolol 50mg is positioned as the market leader for medium-to-large dogs where fewer tablets per dose improves compliance and lowers dispensing costs, offering a competitive price-per-tablet advantage over multiple low-strength tablets. It preserves the beta-1 selectivity benefits of atenolol—reduced bronchial side effects versus propranolol—while trading some dosing flexibility for simpler administration. Compared with sotalol, it remains a more economical option when antiarrhythmic Class III action is not required, though it may necessitate tablet division in smaller patients.

Propranolol 10mg is a commonly used small-dose, non-selective beta blocker favored when clinicians require both peripheral and central beta blockade in small dogs, and its low strength facilitates fine dosing adjustments. Its higher lipophilicity relative to atenolol provides different therapeutic effects in some arrhythmic or stress-related indications, though this can also increase the potential for central side effects and monitoring needs. Financially it is typically low-cost per tablet, making it a practical choice for short-term or adjunctive therapy compared with the more specialized and expensive sotalol.

Propranolol 40mg targets larger patients or high-dose protocols where tablet economy and reduced pill burden are priorities, offering a lower cost-per-dose for clinics treating large-breed dogs. As a non-selective beta blocker it shares the broader physiological effects of propranolol 10mg but with less dosing granularity, which can make it less suitable for small or dose-sensitive patients compared with atenolol 25mg. While generally less expensive than sotalol, it lacks sotalol’s Class III antiarrhythmic capability and therefore is chosen when broad beta blockade rather than rhythm-specific therapy is desired.

Sotalol 80mg is the market leader for canine ventricular arrhythmia management because it combines non-selective beta blockade with Class III potassium-channel blockade, providing rhythm-control advantages that atenolol and propranolol do not. This dual mechanism carries higher monitoring requirements (ECG and renal assessment) and generally higher cost, but it can be clinically and economically justified for dogs with life‑threatening or refractory arrhythmias where fewer hospital interventions offset drug expense. Compared with the atenolol and propranolol options, sotalol is the technical choice when antiarrhythmic potency is the primary therapeutic goal rather than simple rate control or long-term hypertension management.

Sotalol 40mg Tablets are a widely used veterinary beta-blocker with class III antiarrhythmic properties, making them a common first-line choice for managing ventricular and supraventricular arrhythmias in dogs; their predictable effect profile and generic availability make them a cost-effective option for chronic therapy. Compared to Carvedilol 3.125mg, sotalol is often favored when rhythm control is the primary goal because it combines beta-blockade with membrane-stabilizing action, typically requiring simpler titration and lower per-dose cost.